Relapse, rebound, and psoriasis adverse events: An advisory group report - 09/08/11
, Scott Glazer, MD b, Alice B. Gottlieb, MD, PhD c, Mark Lebwohl, MD d, Craig Leonardi, MD e, Alan Menter, MD f, Kim Papp, MD, PhD g, Amy Chen Rundle, MS h, Darryl Toth, MD i
Reprint requests: Wayne Carey, MD, Room A4-17, Royal Victoria Hospital, Department of Dermatology, 687 Pine Ave W, Montreal, Quebec, Canada H3A 1A1.Montreal, Quebec, and Waterloo and Windsor, Ontario, Canada; Buffalo Grove, Illinois; New Brunswick, New Jersey; New York, New York; St. Louis, Missouri; Dallas, Texas; and South San Francisco, California
Abstract |
Psoriasis is a chronic disease, the severity of which varies among patients and changes unpredictably over time in individual patients. Psoriasis can be exacerbated during treatment by infection, endocrine factors, hypocalcemia, medications, psychologic stress, skin trauma, or other factors. Patients who discontinue treatments may experience a return of disease—relapse—or worsening of disease—rebound. The National Psoriasis Foundation (NPF) proposed standardized definitions of relapse and rebound. Efalizumab, a recombinant humanized immunoglobulin G-1 monoclonal antibody, is approved for the management of psoriasis. During efalizumab clinical trials, a small percentage of patients experienced protocol-defined adverse events related to psoriasis. After publication of the NPF definition of rebound, post hoc exploratory analyses of the efalizumab clinical trial data were performed. The efalizumab clinical trial investigators discussed their observations, the analyses, and their individual approaches to the treatment of patients receiving or discontinuing efalizumab therapy, the conclusions of which are described herein.
Le texte complet de cet article est disponible en PDF.Abbreviations used : CD11a, GIF, LMB, NPF, NPF MAB, PASI, PASI-50, PASI-75, PASI-125, PD
Plan
| Supported by Genentech Inc and Serono International SA. Drs Carey and Glazer have no conflict of interest to disclose. Dr Gottlieb is an investigator and consultant for Genentech Inc. Dr Lebwohl or members of his faculty have been investigators for Abbott Laboratories, Amgen Inc, Biogen Idec, Centocor Inc, and Genentech Inc; Dr Lebwohl has also been a consultant or speaker for Allergan, Amgen Inc, Biogen Idec, and Genentech Inc. Dr Leonardi has received educational grant support from and has served on the speakers bureau and advisory board for Genentech Inc. Dr Menter has received research support and/or is a consultant and/or lecturer for Abbott Laboratories, Amgen Inc, Biogen Idec, Centocor Inc, Genentech Inc, Serono International SA, and Xoma, LLC. Dr Papp is a consultant, an investigator, and an advisory board member for Genentech Inc, Serono International SA, and Xoma, LLC; he is on the Serono International SA speakers bureau. Ms Rundle is an employee and a stock shareholder of Genentech Inc. Dr Toth is an investigator and member of the advisory board and speakers bureau for Genentech Inc. |
Vol 54 - N° 4S
P. S171-S181 - avril 2006 Retour au numéro
Article précédent
- Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis
- Kim A. Papp, Bruce Miller, Kenneth B. Gordon, Ivor Caro, Paul Kwon, Peter G. Compton, Craig L. Leonardi, for the Efalizumab Study Group
- Long-term management of plaque psoriasis with continuous efalizumab therapy
- Alan Menter, Craig L. Leonardi, Wolfram Sterry, Jan D. Bos, Kim A. Papp
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?